The largest database of trusted experimental protocols

5 protocols using prolastin

1

Alpha-1 Antitrypsin and Amyloid-beta Oligomers Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Prolastin (Grifols, Barcelona, Spain, for more information see Prolastin-C.pdf">http://www.grifols-pi.info/inserts/Prolastin-C.pdf) was used as a source for A1AT. Prolastin (1 g) was solubilized with 40 ml ultrapure water, aliquoted and stored at -80°C until use.
To obtain Aβ oligomer-enriched preparations, 1 mg Aβ1-42 (Bachem, Bubendorf, Switzerland) was dissolved in 10% ammonia, aliquoted, freeze dried and stored at -80°C. Before use, Aβ1-42 aliquots were dissolved in sterile water (1 mg/ml), and then 100 mM Tris and 50 mM NaCl were added to obtain a 58 μM solution. A magnetic stirrer was added and the Aβ solution was stirred for 48 hours at 1,400 rpm at room temperature.
Antibodies against the following proteins were used: phosphorylated (phospho)-p38, phospho-p44/42, phospho-JNK (c-Jun N-terminal kinase)/SAPK (stress-activated protein kinase), phospho-CREB (all Cell Signaling, Danvers, MA, USA), Aβ (clone 6E10, Covance, Princeton, NJ, USA), A1AT, Vinculin, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Novus Biologicals, Littleton, CO, USA) and horseradish peroxidase-conjugated secondary antibody goat anti-mouse, goat anti-rabbit (both Cell Signaling, Danvers, MA, USA) and donkey anti-goat (Santa Cruz Biotechnology, Dallas, TX, USA).
+ Open protocol
+ Expand
2

Comparative Analysis of A1AT Treatments

Check if the same lab product or an alternative is used in the 5 most similar protocols
Clinical grade A1AT preparations, Zemaira (CSL Behring) and Prolastin® (Grifols) were used in all experiments. Zemaira is also termed A1AT-0 to indicate that it is fatty acid free.
+ Open protocol
+ Expand
3

Purification of alpha-1-antitrypsin from human plasma

Check if the same lab product or an alternative is used in the 5 most similar protocols
Purified human plasma pooled A1AT (Prolastin, Grifols) was used for in vitro experiments. To remove high molecular mass proteins, specifically IgA [16 (link),23 (link),24 (link)] Prolastin was first diluted in phosphate-buffered saline (PBS) and repurified by ultrafiltration using a centricon-100 kDa and centricon-30 kDa cutoff. The IgA-free preparation of A1AT was subjected to quantitative analysis using bicinchoninic acid assay (BCA assay, Pierce BCA Protein Assay Kit, Thermo Scientific) and to qualitative evaluation using Western blot analysis with specific anti-A1AT and anti-IgA antibody.
+ Open protocol
+ Expand
4

Characterization of Protease Inhibitor Interactions

Check if the same lab product or an alternative is used in the 5 most similar protocols
Lipopolysaccharide (from E. coli, L2654), nigericin, BzATP, arachidonic acid (10931), cis-5,8,11,14,17-eicosapentaenoic acid (EPA, E2011), linoleic acid (LA, L1376), oleic acid (OA, O1008), mecamylamine hydrochloride, and strychnine hydrochloride were obtained from Sigma-Aldrich (Taufkirchen, Germany), thapsigargin, ATK, and BEL from Enzo Life Sciences (Lausen, Switzerland), α-bungarotoxin from Tocris Bioscience (Bristol, UK), and Prolastin® from Grifols (Frankfurt, Germany). Conotoxins RgIA4 and ArIB were described previously (11 (link)–13 (link)). Polyclonal goat-anti-AAT was purchased from Bethyl (A80-122A, Montgomery, AL, USA), monoclonal rabbit anti-CD36 antibodies (clone D8L9T) from Cell Signaling Technologies (Danvers, MA, USA), and mouse anti-β-actin antibodies (clone A2228) from Sigma-Aldrich. Horseradish peroxidase-labeled secondary antibodies, rabbit anti-mouse Ig, rabbit anti-goat Ig, and goat anti-rabbit Ig, were provided by Dako (Glostrup, Denmark). The C-terminal peptide of AAT (C-36, corresponding to residues 359–394) was synthesized by JPT Peptide Technologies GmbH (Berlin, Germany) and provided with a purity of >95% (HPLC).
+ Open protocol
+ Expand
5

Conopeptide RgIA4 and AAT Infusion

Check if the same lab product or an alternative is used in the 5 most similar protocols
All animals of the AAT group received the human AAT preparation Prolastin (Grifols, Frankfurt, Germany), 100 mg/kg bodyweight, infused by a syringe pump (Model 11 Plus, Harvard Apparatus, Cambridge, UK) over 5 min after cannulation of the lateral tail vein. The conopeptide RgIA4 was produced and characterized as described before45 (link). RgIA4 was administered after positioning of the venous line as a bolus of 2 nmol and thereafter, added to the continuous infusion at a concentration of 38.8 nmol/kg/h. AAT was infused after the bolus injection of RgIA4 in the subgroup treated with both drugs. Afterwards, the continuous infusion containing RgIA4 was started. Animals of the other groups received sodium chloride 0.9% as a vehicle instead of AAT and/or RgIA4.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!